Neimeth International Pharmaceuticals Q1 2026 Board Meeting Outcome
Neimeth International Pharmaceuticals Plc has disclosed that its Board of Directors, at a meeting held on 28th April 2026, approved the company's Unaudited Financial Statements for the first quarter ended 31st March 2026. The filing confirms the statements will be submitted to the Nigerian Exchange Limited on or before 30th April 2026.
Neimeth International Pharmaceuticals Plc notified the Nigerian Exchange Limited (NGX) and the investing public on 29th April 2026 of the outcome of its Board of Directors' meeting held the previous day, Tuesday 28th April 2026.
At that meeting, the Board approved the company's Unaudited Financial Statements (UFS) for the first quarter ended 31st March 2026, referred to as the 2026 Q1 UFS. The company stated that the approved financial statements would be filed with the NGX on or before 30th April 2026.
In connection with the preparation of these financials, a closed period had previously been announced, restricting Insiders and connected persons from trading in the company's shares. Neimeth confirmed that this closed period will remain in effect until twenty-four hours after the 2026 Q1 Unaudited Financial Statements are officially released to the public.
The notice was signed by Chinenye S. Adekanmbi, the Company Secretary. No financial figures, revenue data, or profit disclosures were included in this particular filing, which is limited to reporting the board's procedural approval and the status of the trading restriction.
